DARE Dare Bioscience, Inc.

Nasdaq darebioscience.com


$ 2.10 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:46:18 EDT
QQQ $ 592.66 $ 0.00 (0 %)
DIA $ 455.78 $ 0.00 (0 %)
SPY $ 653.92 $ 0.00 (0 %)
TLT $ 91.55 $ 0.00 (0 %)
GLD $ 399.77 $ 0.00 (0 %)
$ 2.12
$ 2.08
$ 2.10 x 197
$ 2.20 x 20
-- - --
$ 1.83 - $ 9.19
1,286,691
na
28.58M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-28-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-02-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dar-bioscience-secures-up-to-499k-from-gates-foundation-to-support-preeclampsia-research-through-mentorship-and-project-management

Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health bet...

 maxim-group-upgrades-dare-bioscience-to-buy-announces-8-price-target

Maxim Group analyst Caroline Palomeque upgrades Dare Bioscience (NASDAQ:DARE) from Hold to Buy and announces $8 price target.

 dare-bioscience-q2-eps-045-beats-061-estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.6...

 dar-bioscience-launch-phase-one-of-patient-focused-campaign-with-rosy-wellness-to-support-dare-to-play-sildenafil-cream

A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need...

 dar-bioscience-collaborates-with-rosy-wellness-to-educate-and-market-dare-to-play-sildenafil-cream

Collaboration will leverage Rosy Wellness' extensive reach and community of over 250,000 womenRosy Wellness is a multi-awar...

 dare-bioscience-q1-eps-050-up-from-081-yoy-sales-2543k-up-from-930k-yoy

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.50) per share. This is a 38.27 percent increase over losses of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION